 |
 |
| top viewed article of the day |
The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study
Sverre E. Kjeldsen, MD; Paulette A. Lyle, BS; Jorge R. Kizer, MD; Björn Dahlöf, MD; Richard B. Devereux, MD; Stevo Julius, MD; Gareth Beevers, MD; Ulf de Faire, MD; Frej Fyhrquist, MD; Hans Ibsen, MD; Krister Kristianson, PhD; Ole Lederballe-Pedersen, MD; Lars H. Lindholm, MD; Markku S. Nieminen, MD; Per Omvik, MD; Suzanne Oparil, MD; Steven M. Snapinn, PhD; Katherine E. Harris, DrPH; Hans Wedel, PhD;
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH). Patients aged 55-80 years with blood pressures 160-200/<90 mm Hg were followed for a mean of 4.7 years. Blood pressure was similarly reduced in the losartan (n=660) and atenolol (n=666) ISH groups. There were 88 (6.6%) patients who experienced a stroke, 18 of which were fatal. Of patients experiencing strokes, 72.7% had an ischemic stroke. ISH patients in LIFE compared to the non-ISH group had a higher incidence of any stroke and embolic stroke, and similar incidences of fatal, atherosclerotic, and hemorrhagic/other strokes. The incidence of any stroke (40% risk reduction [RR], p=0.02), fatal stroke (70% RR, p=0.035), and atherothrombotic stroke (45% RR, p=0.022) was significantly lower in losartan-treated compared to the atenolol-treated patients. The 36% RR for embolic strokes in the losartan group was not statistically significantly (p=0.33) different from the atenolol group. These data suggest that losartan-based treatment is more effective than an atenolol-based treatment for patients with ISH and a high risk for stroke. |
| J Clin Hypertens(2005) 7;3:152-158 |
|
 |
|
| latest NO FEE INSTANT CME courses |
Obstructive Sleep Apnea and Hypertension
The Journal of Clinical Hypertension®
|
1.0 AMA/PRA Credit |
Improving Blood Pressure Control: Increase the Dose of Diuretic or Switch to a Fixed-Dose Angiotensin Receptor Blocker/Diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTATE) Trial
The Journal of Clinical Hypertension®
|
1.0 AMA/PRA Credit |
Varenicline and Its Role in Smoking Cessation
Preventive Cardiology™
|
1.0 AMA/PRA Credit |
Salt-Resistant and Salt-Sensitive Phenotypes Determine the Sensitivity of Blood Pressure to Weight Loss in Overweight/Obese Patients
The Journal of Clinical Hypertension®
|
1.0 AMA/PRA Credit |
Challenges to the Diagnosis, Evaluation, Treatment and Management of Clustered Cardiometabolic Risk Factors
Journal of the CardioMetabolic Syndrome
|
1.0 AMA/PRA Credit |
| Enter our Manuscript Submission System |
 |
| Employment Opportunities |
 |
|
|
|
|
 |
FULL TEXT SEARCH [BETA 0.3] |
|
ADVANCED SEARCH OPTIONS |
 |
The American Heart Hospital Journal
Winter 2008
|
 |
The American Journal of Geriatric Cardiology
March/April 2008
|
 |
Congestive Heart Failure
July/August 2008
|
 |
Journal of the Cardiometabolic Syndrome
Spring 2008
|
|
The Journal of Clinical Hypertension
August 2008
|
 |
Preventive Cardiology
Summer 2008
|
 |
SKINmed: Dermatology for the Clinician
March/April 2008
|
|
|
|
|
|
|
|
